← All Signals

🏥 FDA: The Harvard Drug Group LLC — Class II

healthcarebearishSource: FDA
75%Confidence
0Views
FDASource
2026-03-17Date

Summary

Defective blister packaging for Midodrine tablets creates patient safety concerns and potential liability for The Harvard Drug Group, possibly leading to increased regulatory oversight of their packaging operations. This packaging failure could disrupt supply of this blood pressure medication and trigger competitor gains.

Actionable: Verify packaging integrity for products from Major Pharmaceuticals and consider temporary alternative suppliers for Midodrine.

AI Confidence: 75%

Data Points

firmThe Harvard Drug Group LLC
classificationClass II
statusOngoing
distributionNationwide US.
productMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapol

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now